Enliven Therapeutics (NASDAQ:ELVN) Coverage Initiated at Barclays

Research analysts at Barclays assumed coverage on shares of Enliven Therapeutics (NASDAQ:ELVN) in a research report issued on Tuesday,Benzinga reports. The firm set an “overweight” rating and a $78.00 price target on the stock. Barclays‘s price objective would suggest a potential upside of 31.03% from the stock’s previous close.

ELVN has been the topic of a number of other reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Friday, July 17th. HC Wainwright lifted their price target on shares of Enliven Therapeutics from $56.00 to $64.00 and gave the company a “buy” rating in a research report on Thursday, July 9th. JonesTrading lifted their price target on shares of Enliven Therapeutics from $45.00 to $70.00 and gave the company a “buy” rating in a research report on Monday, June 29th. Guggenheim dropped their price objective on shares of Enliven Therapeutics from $80.00 to $78.00 and set a “buy” rating on the stock in a research note on Thursday, August 6th. Finally, Mizuho upped their price objective on shares of Enliven Therapeutics from $62.00 to $73.00 and gave the stock an “outperform” rating in a report on Tuesday. Seven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Enliven Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $75.00.

Enliven Therapeutics Stock Performance

Shares of NASDAQ:ELVN opened at $59.53 on Tuesday. The firm has a market capitalization of $4.36 billion, a P/E ratio of -35.65 and a beta of 0.27. The stock has a 50 day moving average price of $51.42 and a 200-day moving average price of $41.13. Enliven Therapeutics has a 52-week low of $14.78 and a 52-week high of $62.32.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.10). On average, equities analysts forecast that Enliven Therapeutics will post -1.67 EPS for the current fiscal year.

Insider Activity at Enliven Therapeutics

In other Enliven Therapeutics news, Director Lori Anne Kunkel sold 10,000 shares of Enliven Therapeutics stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $50.49, for a total value of $504,900.00. Following the completion of the transaction, the director directly owned 41,884 shares of the company’s stock, valued at approximately $2,114,723.16. The trade was a 19.27% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mika K. Derynck sold 158,795 shares of the company’s stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $60.21, for a total transaction of $9,561,046.95. Following the completion of the transaction, the director owned 87,373 shares in the company, valued at approximately $5,260,728.33. This represents a 64.51% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 190,831 shares of company stock valued at $10,991,723. 3.00% of the stock is owned by insiders.

Institutional Investors Weigh In On Enliven Therapeutics

A number of institutional investors have recently made changes to their positions in ELVN. KBC Group NV bought a new position in Enliven Therapeutics in the 1st quarter valued at approximately $38,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in Enliven Therapeutics by 25.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock valued at $44,000 after purchasing an additional 594 shares during the last quarter. BNP Paribas Financial Markets increased its holdings in shares of Enliven Therapeutics by 33.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock worth $75,000 after purchasing an additional 930 shares in the last quarter. Los Angeles Capital Management LLC purchased a new position in shares of Enliven Therapeutics in the fourth quarter worth $83,000. Finally, Quantbot Technologies LP raised its stake in shares of Enliven Therapeutics by 47.1% in the second quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock worth $90,000 after purchasing an additional 1,434 shares during the last quarter. Hedge funds and other institutional investors own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.